Safety and Efficacy of Multiple Drug Resistant Tuberculosis Treatment in Patients with Different HIV Statuses
https://doi.org/10.21292/2075-1230-2022-100-1-33-40
Abstract
The objective: to analyze and compare frequency and variety of adverse events (AEs) and their impact on outcomes of tuberculosis therapy when treating patients with multiple drug resistant tuberculosis (MDR TB) and different HIV statuses.
Subjects and Methods: retrospective observational case-control study of patients registered for treatment with the 4th regimen of chemotherapy for tuberculosis in the city of Vladimir and Vladimir Region in 2014-2016.
Results. The proportion of patients who reported any AE during the MDR TB treatment was similar among HIV positive and HIV negative patients and made 85.5%. In patients with concurrent HIV infection and MDR TB, hematopoietic AEs such as anemia, thrombocytopenia were more frequent, while neutropenia was significantly more frequent when comparing groups by the cumulative event probability method. Elevated eosinophil level during treatment was more typical of MDR TB patients. Treatment outcomes in the group of patients with HIV and MDR TB were statistically significantly worse due to the higher frequency of fatal outcomes. At the same time, there was no correlation of AE with unfavorable treatment outcomes. The early initiation of combination therapy with thorough monitoring of hematologic parameters in patients with HIV and MDR TB was safe and effective.
About the Authors
S. Yu. Degtyareva
RUDN University
Russian Federation
Russian Federation
Svetlana Yu. Degtyareva - Assistant of Infectious Diseases Department with Training Courses in Epidemiology and Phthisiology of the Medical Institute
Phone/Fax: +7 (495) 365-25-33
6, Miklukho-Maklaya St., Moscow, 117198
V. N. Zimina
RUDN University; National Medical Research Center of Phthisiopulmonology and Infectious Diseases
Russian Federation
Russian Federation
Vera N. Zimina - Doctor of Medical Sciences, Professor of Infectious Diseases Department with Training Courses in Epidemiology and Phthisiology of the Medical Institute
Phone/Fax: +7 (495) 365-25-33
6, Miklukho-Maklaya St., Moscow, 117198
А. V. Pokrovskaya
RUDN University; Central Research Institute of Epidemiology, the Federal Service on Customers' Rights Protection and Human Well-being Surveillance
Russian Federation
Russian Federation
Anastasia V. Pokrovskaya - Candidate of Medical Sciences, Associate Professor of Infectious Diseases Department with Training Courses in Epidemiology and Phthisiology of the Medical Institute
Phone: +7 (495) 974-96-46
6, Miklukho-Maklaya St., Moscow, 117198
G. V. Volchenkov
Vladimir Regional Center for Specialized Phthisiopulmonary Care
Russian Federation
Russian Federation
Grigory V. Volchenkov - Head Physician
Phone: +7 (492) 242-50-92
63, Sudogodskoye Rd., Vladimir, 600023
References
1. Zimina V.N., Vasilyeva I.А., Batyrov F.А., Yarovaya Zh.Yu. The specific course of tuberculosis in the advanced stages of HIV infection. Tuberculosis and Lung Diseases, 2010, no. 3, pp. 23-27. (In Russ.)
2. All-Russia Non-Commercial Organization of the Russian Society of Phthisiologists, Tuberkulez u vzroslykh. Klinicheskie rekomendatsii. [Tuberculosis in adults. Guidelines]. 2020, pp. 121. Available: https://cr.minzdrav.gov.ru/recomend/16_1.
3. Rossiyskoe Obschestvo Ftiziatrov Publ., Federalnye klinicheskie rekomendatsii po diagnostike i lecheniyu tuberkuleza u bolnykh VICH-infektsiey. [Federal clinical recommendations on diagnostics and treatment of tuberculous in HIV patients]. Moscow, 2014, 34 p. Available: http://roftb.ru/netcat_files/doks2015/rec4.pdf
4. Bisson G.P., Bastos M., Campbell J.R., Bang D., Brust J.C., Isaakadis P. et al. Mortality in adults with multidrug-resistant tuberculosis and HIV by antiretroviral therapy and tuberculosis drug use: an individual patient data meta-analysis. Lancet, 2020, vol. 396, no. 10248, pp. 402-411.
5. Conradie F., Mabiletsa T., Sefoka M., Mabaso S., Louw R., Evans D. et al. Prevalence and incidence of symmetrical symptomatic peripheral neuropathy in patients with multidrug-resistant TB. South African Med. J., 2014, vol. 104, no. 1, pp. 24-26.
6. DAIDS Table for Grading the Severity of Adult and Pediatric Adverse Events. Corrected version 2.1 [Epub]. Available: https://rsc.niaid.nih.gov/sites/default/files/daidsgradingcorrectedv21.pdf (Accessed: 24.06.2021).
7. Gray R. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann. Stat., 1988, no. 16, pp. 1141-1154.
8. hiv-druginteractions [Epub.]. Available: https://www.hiv-druginteractions.org/checker (Accessed: 24.06.2021).
9. Hong H., Budhathoki C., Farley J.E. Increased risk of aminoglycoside-induced hearing loss in MDRTB patients with HIV coinfection. Intern. J. Tuberc. Lung Dis., 2018, vol. 6, no. 22, pp. 667-674.
10. Huerga H., Bastard M., Kamene M., Wanjala S., Arnold A., Oucho N. et al. Outcomes from the first multidrug-resistant tuberculosis programme in Kenya. Intern. J. Tuberc. Lung Dis., 2017, vol. 3, no. 21, pp. 314-319.
11. Mesfin Y.M., Hailemariam D., Biadglign S., Kibret K.T., Glaziou P. Association between HIV/AIDS and Multi-Drug Resistance Tuberculosis: A Systematic Review and Meta-Analysis. Shukla D., editor. PLoS ONE, 2014, vol. 1, no. 9, pp. e82235.
12. Schnippel K., Berhanu R.H., Black A., Firnhaber C., Maitisa N., Evans D. et al. Severe adverse events during second-line tuberculosis treatment in the context of high HIV Co-infection in South Africa: A retrospective cohort study. BMC Infect. Dis., 2016, vol. 1, no. 16, pp. 1-10.
13. Scrucca L., Santucci A., Aversa F. Competing risk analysis using R: An easy guide for clinicians. Bone Marrow Transplantation, 2007, vol. 4, no. 40, pp. 381-387.
14. Smith J.P., Gandhi N.R., Shah N.S., Mlisana K., Moodley P., Johnson B.A. et al. The Impact of Concurrent Antiretroviral Therapy and MDR-TB Treatment on Adverse Events. J. Acquired Immune Deficiency Syndromes, 2020, vol. 1, no. 83, pp. 47-55.
15. WHO consolidated guidelines on drug-resistant tuberculosis treatment, 2019. Available: https://www.who.int/publications/i/item/9789240007048.
16. WHO treatment guidelines for drug-resistant tuberculosis, 2016. Available: https://www.who.int/publications/i/item/9789241549639.
17. World Health Organisation End TB Strategy. World Health Organization. 2013, vol. 9, no. 53, pp. 1689-1699.
18. Wu S., Zhang Y., Sun F., Chen M., Zhou L., Wang N., et al. Adverse events associated with the treatment of multidrug-resistant tuberculosis: A systematic review and meta-analysis. Am. J. Therapeutics, 2016, vol. 2, no. 23, pp. e521-530.
Review
For citations:
Degtyareva S.Yu., Zimina V.N., Pokrovskaya А.V., Volchenkov G.V. Safety and Efficacy of Multiple Drug Resistant Tuberculosis Treatment in Patients with Different HIV Statuses. Tuberculosis and Lung Diseases. 2022;100(1):33-40. (In Russ.) https://doi.org/10.21292/2075-1230-2022-100-1-33-40
Views:
750
Email this article 